-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

Benzinga·07/16/2026 14:57:28
Listen to the news
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.